Summary of Incyte Q3 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenues:: $1.37 billion, a 20% increase year-over-year.

Product Sales:: $1.15 billion, a 19% increase year-over-year.

Jakafi Sales:: $791 million, up 7% year-over-year, with a 10% increase in demand.

Opzelura Sales:: $188 million, a 35% increase year-over-year.

R&D Expenses:: $507 million, a 7% increase year-over-year.

SG&A Expenses:: $329 million, a 6% increase year-over-year.

Full-Year Guidance:: Raised net product revenue guidance to $4.23 billion - $4.32 billion, with operating expenses maintained at $3.25 billion - $3.31 billion.

2Strategic Updates and Business Highlights

Jakafi:: Strong performance across all indications, with increased market share in myelofibrosis (MF) and graft-versus-host disease (GvHD). Full-year guidance for Jakafi raised to $3.05 billion - $3.075 billion.

Opzelura:: Significant growth driven by strong prescription demand and favorable formulary placements. Plans for EU application for moderate atopic dermatitis (AD) by year-end.

Niktimvo:: Continued strong adoption with $46 million in sales, capturing 13% of the GvHD market in nine months post-launch. Positive feedback from transplant centers.

Pipeline Focus:: Streamlining R&D to prioritize high-impact programs, including mCALR for MF and other solid tumor therapies. Several preclinical programs were paused or terminated to focus resources on more promising candidates.

New Product Launches:: Anticipated launches include ruxolitinib XR, Opzelura AD in Europe, and povorcitinib for hidradenitis suppurativa (HS).

3Forward Guidance and Outlook

2025 Guidance:: Increased product revenue guidance reflects strong sales momentum. The company aims to maintain operational discipline while investing in key growth areas.

Long-Term Growth Strategy:: Focus on fewer, high-value projects to ensure sustainable growth post-Jakafi LOE in 2029. The goal is to build a robust pipeline that can support revenue streams into the next decade.

4Bad News, Challenges, or Points of Concern

Pipeline Adjustments:: The termination of several programs, including the BET inhibitor and povorcitinib for chronic spontaneous urticaria, indicates a strategic shift towards prioritizing higher-return projects, which may raise concerns about the breadth of the pipeline.

Competitive Pressures:: The need to differentiate mCALR and other therapies in a competitive landscape, particularly in the context of existing treatments like Jakafi and Rezurock.

Regulatory Risks:: Uncertainty around FDA guidance for pivotal trial endpoints for mCALR and the potential challenges in proving efficacy against existing therapies.

5Notable Q&A Insights

mCALR Program:: There is a strong emphasis on demonstrating single-agent efficacy in the upcoming data release, with benchmarks set against existing treatments.

Niktimvo's Growth:: Management expressed confidence in the sustainability of Niktimvo's growth trajectory, citing broad adoption among transplant centers and positive feedback.

Combination Studies:: The company is exploring both monotherapy and combination therapy approaches for mCALR, with a focus on addressing the needs of both treatment-naive and previously treated patients.

Operational Efficiency:: Management is committed to balancing cost control with strategic investments to support long-term growth, indicating a proactive approach to managing expenses. Overall, Incyte's Q3 2025 performance reflects strong revenue growth and strategic focus on high-potential products, while also navigating challenges in its pipeline and competitive landscape.